INTRODUCTION
Evaluation of the axilla provides information for treatment decisions in patients with invasive breast cancer. Axillary lymph node dissection (ALND) is the standard initial approach for breast cancer patients who are clinically node positive. Sentinel node biopsy is the standard initial approach for patients with early-stage breast cancer who are clinically node negative.The technique of ALND will be reviewed here. The approach to management of the regional lymph nodes in breast cancer, sentinel node biopsy indications and outcomes, sentinel node biopsy techniques, and effect of ALND on patient survival are discussed elsewhere. (See "Overview of management of the regional lymph nodes in breast cancer" and "Overview of sentinel lymph node biopsy in breast cancer" and "Sentinel lymph node biopsy in breast cancer: Techniques".)
INDICATIONS
An axillary lymph node dissection (ALND) is performed with the primary breast procedure (eg, lumpectomy or mastectomy) in patients who have:
●Locally advanced (T3-T4; N0-2) or inflammatory breast cancer. (See "Overview of sentinel lymph node biopsy in breast cancer", section on 'Contraindications'.)
●Needle-biopsy-proven metastatic disease in axillary lymph node(s), which are either clinically palpable or nonpalpable but abnormal by imaging (mostly ultrasound) criteria. (See "Overview of sentinel lymph node biopsy in breast cancer", section on 'Preoperative axilla evaluation'.)